单胺氧化酶B抑制剂联合普拉克索治疗帕金森病的效果及对Hcy和5-HT水平的影响  

Therapeutic effect of monoamine oxidase B inhibitor combined with pramipexole on Parkinson disease and its influence on levels of Hcy and 5-HT

作　　者：王晶 廖磊 秦丽娜 Wang Jing;Liao Lei;Qin Lina(Department of Neurology,the First People’s Hospital of Zhumadian,Zhumadian 463000,China)

机构地区：[1]驻马店市第一人民医院神经内科,驻马店463000

出　　处：《中国实用医刊》2024年第7期98-101,共4页Chinese Journal of Practical Medicine

摘　　要：目的观察单胺氧化酶B抑制剂联合普拉克索治疗帕金森病的效果,分析联合用药对患者同型半胱氨酸(Hcy)及5-羟色胺(5-HT)水平的影响。方法前瞻性研究。抽取2021年2月至2023年4月于驻马店市第一人民医院接受治疗的92例帕金森病患者,按随机数字表法分为对照组和观察组,每组46例。两组均接受常规对症治疗,对照组使用普拉克索,观察组在对照组的治疗基础上联合使用单胺氧化酶B抑制剂。两组均治疗3个月。比较两组疗效及治疗期间不良反应发生情况。比较两组治疗前及治疗3个月后血清细胞因子(Hcy、5-HT)水平。结果观察组治疗总有效率(97.83%,45/46)高于对照组(82.61%,38/46),P<0.05。治疗前,两组Hcy、5-HT水平比较差异未见统计学意义(P>0.05);治疗3个月后,两组血清Hcy水平降低,5-HT水平上升,且观察组血清Hcy水平低于对照组,血清5-HT水平高于对照组(P<0.05)。观察组治疗期间不良反应发生率(13.04%,6/46)与对照组(8.70%,4/46)比较差异未见统计学意义(P>0.05)。结论单胺氧化酶B抑制剂联合普拉克索治疗帕金森病,可有效调节患者Hcy、5-HT水平,提高整体治疗效果,且不会增加不良反应,安全性高。Objective To observe the efficacy of monoamine oxidase B inhibitor combined with pramipexole in the treatment of Parkinson disease,and to analyze the impact of combined therapy on the levels of homocysteine(Hcy)and 5-hydroxytryptamine(5-HT)in patients.Methods A prospective study was conducted,including 92 patients with Parkinson disease who received treatment in the First People’s Hospital of Zhumadian from February 2021 to April 2023.And they were divided into a control group and an observation group using a random number table method,with 46 cases in each group.Both groups received routine symptomatic treatment.In addition,the control group was treated with pramipexole,and the observation group was treated with monoamine oxidase B inhibitor based on the treatment of the control group.Patients in the two groups were treated for 3 months.The treatment efficacy and incidence of adverse reactions during the treatment of the two groups were compared.The preoperative and 3-month postoperative levels of serum cytokines(Hcy,5-HT)of the two groups were compared.Results The total effective rate of the observation group(97.83%,45/46)was higher than that of the control group(82.61%,38/46),P<0.05.There was no significant difference in levels of Hcy and 5-HT between the two groups before treatment(P>0.05).After 3 months of treatment,levels of Hcy decreased,and levels of 5-HT increased in both groups(P<0.05);and the observation group had lower level of Hcy but higher level of 5-HT compared with the control group(P<0.05).There was no statistical significant difference in the incidence of adverse reactions between the observation group(13.04%,6/46)and the control group(8.70%,4/46)during the treatment period(P>0.05).Conclusions Monoamine oxidase B inhibitor combined with pramipexole in the treatment of Parkinson disease can effectively regulate the levels of Hcy and 5-HT,improve the overall treatment effect,and do not increase adverse reactions,which is safe and reliable.

关 键 词：帕金森病 单胺氧化酶B抑制剂 普拉克索 同型半胱氨酸 5-羟色胺 

分 类 号：R742.5[医药卫生—神经病学与精神病学]